Cargando…

Integrase inhibitors: Why do we need a new drug class for HIV therapy?

Detalles Bibliográficos
Autor principal: Rockstroh, Jürgen Kurt
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3516821/
https://www.ncbi.nlm.nih.gov/pubmed/19959410
http://dx.doi.org/10.1186/2047-783X-14-S3-1
_version_ 1782252347226849280
author Rockstroh, Jürgen Kurt
author_facet Rockstroh, Jürgen Kurt
author_sort Rockstroh, Jürgen Kurt
collection PubMed
description
format Online
Article
Text
id pubmed-3516821
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-35168212012-12-11 Integrase inhibitors: Why do we need a new drug class for HIV therapy? Rockstroh, Jürgen Kurt Eur J Med Res Review BioMed Central 2009-11-24 /pmc/articles/PMC3516821/ /pubmed/19959410 http://dx.doi.org/10.1186/2047-783X-14-S3-1 Text en Copyright ©2009 I. Holzapfel Publishers
spellingShingle Review
Rockstroh, Jürgen Kurt
Integrase inhibitors: Why do we need a new drug class for HIV therapy?
title Integrase inhibitors: Why do we need a new drug class for HIV therapy?
title_full Integrase inhibitors: Why do we need a new drug class for HIV therapy?
title_fullStr Integrase inhibitors: Why do we need a new drug class for HIV therapy?
title_full_unstemmed Integrase inhibitors: Why do we need a new drug class for HIV therapy?
title_short Integrase inhibitors: Why do we need a new drug class for HIV therapy?
title_sort integrase inhibitors: why do we need a new drug class for hiv therapy?
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3516821/
https://www.ncbi.nlm.nih.gov/pubmed/19959410
http://dx.doi.org/10.1186/2047-783X-14-S3-1
work_keys_str_mv AT rockstrohjurgenkurt integraseinhibitorswhydoweneedanewdrugclassforhivtherapy